press releases

Data suggest combined modality treatment with TTFields and triplet combination chemotherapy may extend survival in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that four abstracts focusing on Tumor Treating Fields (TTFields) will be presented at the upcoming 69th American Academy of… Read More

Data show glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived longer than patients who received bevacizumab alone ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that data from a post hoc analysis of the EF-14 pivotal phase 3 clinical trial of Optune… Read More

Final analyses provide unprecedented five-year survival advantage reinforcing Optune plus temozolomide as a combination treatment for glioblastoma patients Survival benefit was maintained in all patient subgroups, including those with the worst prognostic features ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today final results from its… Read More

Phase 2 pilot PANOVA data presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls… Read More

Phase 2 pilot INNOVATE data will be presented at the American Association for Cancer Research Annual Meeting 2017 Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)–… Read More

Interim results from the STELLAR trial, presented in December 2016, suggest improvements in progression free survival and one-year survival rates when TTFields is added to standard chemotherapy ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the STELLAR trial, a… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2017 on Thursday, April 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the 16th Annual Needham & Company Healthcare Conference on April 5, 2016, in New York. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More

Second generation Optune is now approved in all active Novocure markets Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today announced that… Read More